Moderate

Surgical VTE prophylaxis

VTE · Wounds & Procedures
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Surgical patients are at high risk of venous thromboembolism. Risk-assessed mechanical and pharmacological prophylaxis, balanced against bleeding risk, substantially reduces DVT and fatal pulmonary embolism.

Red flags

  • Active major bleeding
  • Falling platelets on heparin (suspect HIT)
  • Signs of established DVT/PE (unilateral leg swelling, pleuritic chest pain, hypoxia)
  • Neuraxial block with recent/planned anticoagulant (spinal haematoma risk)
  • Severe thrombocytopenia

Assessment

Differential diagnosis

  • High VTE-risk surgical patient
  • High bleeding-risk patient (prophylaxis contraindicated)
  • Established DVT / PE
  • Heparin-induced thrombocytopenia
  • Cancer-associated thrombosis
  • Patient on prior anticoagulation needing bridging

Investigations

  • Formal VTE and bleeding risk assessment on admission and reassess
  • FBC (baseline platelets), U&E (renal dosing), coagulation screen
  • Weight for weight-based dosing
  • Doppler/CTPA only if VTE clinically suspected
  • Platelet monitoring if on heparin (HIT surveillance)
  • Review anticoagulant/antiplatelet medication history

Management

  • Perform a documented VTE risk assessment for every surgical admission
  • Weigh thrombotic risk against bleeding risk for each patient
  • Apply mechanical prophylaxis (anti-embolism stockings and/or intermittent pneumatic compression), excluding peripheral arterial disease
  • Encourage early mobilisation and adequate hydration
  • Start pharmacological prophylaxis (LMWH) when bleeding risk is acceptable, timed around surgery
  • Adjust LMWH dose for renal impairment and extremes of body weight
  • Provide extended prophylaxis (up to 28 days) after major abdominal/pelvic cancer and major orthopaedic surgery
  • Avoid pharmacological prophylaxis with active bleeding, severe thrombocytopenia or near neuraxial procedures
  • Monitor platelets and consider HIT if counts fall
  • Review prophylaxis daily and on discharge
  • Manage patients on therapeutic anticoagulation with an individualised peri-operative plan
  • Educate patients on signs of DVT/PE and extended prophylaxis compliance

Drugs & doses

Enoxaparin 40 mg SC OD (reduce to 20 mg OD or adjust in severe renal impairment)
Dalteparin 5000 units SC OD as alternative LMWH
Unfractionated heparin 5000 units SC BD/TDS if severe renal impairment
Fondaparinux 2.5 mg SC OD (e.g. HIT or orthopaedic protocols)
Intermittent pneumatic compression devices as mechanical prophylaxis

Disposition

Inpatient prophylaxis per hospital policy with daily review; arrange extended prophylaxis and patient education at discharge where indicated. Escalate suspected VTE or HIT.

Complications & pitfalls

  • Pulmonary embolism (potentially fatal)
  • Deep vein thrombosis / post-thrombotic syndrome
  • Bleeding from prophylaxis
  • Heparin-induced thrombocytopenia
  • Spinal/epidural haematoma with neuraxial anaesthesia

Exam pearls

  • Every surgical admission needs a documented VTE and bleeding risk assessment
  • Extended 28-day prophylaxis is standard after major pelvic/abdominal cancer and many major orthopaedic procedures
  • Respect the timing interval between LMWH doses and neuraxial block/catheter removal
  • A drop in platelets on heparin should trigger HIT consideration and alternative anticoagulation

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.